Trial · NCT02807103
Rituximab in Eosinophilic Granulomatosis With Polyangiitis
NCT02807103, Phase 3, Completed, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rituximab in Eosinophilic Granulomatosis With Polyangiitis. Trials, record NCT02807103. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02807103
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rituximab in Eosinophilic Granulomatosis With Polyangiitis
- NCT number
- NCT02807103
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 107 participants, actual
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Interventions
- Rituximab, Placebo-rituximab, Cyclophosphamide, Placebo-cyclophosphamide
- First posted
- 2016-06-21
- Last updated
- 2026-01-15
- Other registries' IDs
- eudract:2016-000275-25
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The percentage of patients who obtained a BVAS=0 and prednisone dose ≤7.5 mg/day at day 180. | 180 days | |
| Secondary | Number of adverse events | 180 days | expressed as adverse events according to the CTCAE toxicity grading system per patient-year for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, hemorrhagic cystitis, malignancies, venous thromboembolic events, hospitalization resulting either from the disease or from a complication due to the study treatment, infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions |
| Secondary | Number of adverse events | 360 days | expressed as adverse events according to the CTCAE toxicity grading system per patient-year for the following adverse events combined: death (all causes), grade 2 or higher leukopenia or thrombocytopenia, grade 3 or higher infections, hemorrhagic cystitis, malignancies, venous thromboembolic events, hospitalization resulting either from the disease or from a complication due to the study treatment, infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions |
| Secondary | Area under the curve for corticosteroids | 180 days | To measure the corticosteroid dose and to compare the corticosteroid sparing effect of rituximab versus conventional therapy |
| Secondary | Area under the curve for corticosteroids | 360 days | To measure the corticosteroid dose and to compare the corticosteroid sparing effect of rituximab versus conventional therapy |
| Secondary | Number of sequelae assessed by the Vasculitis Damage Index | 180 days | |
| Secondary | Number of sequelae assessed by the Vasculitis Damage Index | day 180 and day 360 | |
| Secondary | ANCA titers and CD19+cells | day 180 and day 360 | |
| Secondary | Health Assessment Questionnaire (HAQ) score | 180 days | to evaluate functional disability |
| Secondary | Health Assessment Questionnaire (HAQ) score | 360 days | to evaluate functional disability |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40720835 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02807103
GET https://conductscience.org/api/trials/v1/NCT02807103/registered